NICE
NICE rejects Pfizer’s Vyndaqel for treating rare heart condition
May 12, 2021Research and Development NICE, Pfizer, Vyandaqel
NICE has published final guidance today which rejects tafamidis, also known as Vyndaqel, for treating rare heart condition transthyretin amyloidosis …
NICE rejects Merck Serono’s Bavencio for urothelial cancer
May 10, 2021Sales and Marketing MSD, Merck, NHS, NICE, cancer treatment, pharma, pharma news
The use of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy is not recommended by …
NICE finds more SMA patients eligible for £75,000 a vial drug
May 4, 2021Manufacturing and Production, Sales and Marketing NICE, sma
NICE has announced that more people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from nusinersen, …
NICE to join GetReal Institute alongside nine key healthcare players
April 28, 2021Research and Development EU, NICE, rwe
NICE has announced it will join with nine other organisations to form the GetReal Institute, a not-for-profit multi-stakeholder enterprise, as …
NICE updates guidelines on atrial fibrillation based on new evidence
April 27, 2021Manufacturing and Production NICE
NICE has updated its guideline on the diagnosis and management of atrial fibrillation (AF) based on new evidence found since …
Novartis multiple sclerosis treatment recommended by NICE
April 20, 2021Manufacturing and Production NICE, Novartis, multiple sclerosis, pharma, pharma news
NICE have recommenced Novartis’ ofatumumab (Kesimpta) for the treatment of relapsing remitting MS (RRMS) in adult patients for use on …
NICE launch ambitious five-year patient access strategy
April 19, 2021Sales and Marketing NICE
NICE has unveiled its five-year plan to speed up patients’ access to the latest and most effective treatments with increased …
First approved C5 complement inhibitor recommended by NICE for NHS use
April 15, 2021NHS, NICE
NICE has recommended Ultomiris (ravulizumab) for use in the NHS for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adult …
NICE recommends CBT, acupuncture, and anti-depressants for chronic pain
April 7, 2021Research and Development NICE, antidepressant, chronic pain
A new NICE guideline on the assessment and management of chronic primary pain does not recommend the prescription of painkillers, …
NICE recommends Kineret for Still’s disease treatment
April 1, 2021NICE
Sobi has today announced a NICE recommendation of Kineret (anakinra) as a first-line biologic therapeutic option for still’s disease, including …
The Truth Behind the £1.8 Million Drug
March 31, 2021Manufacturing and Production FDA, NHS, NICE
As NICE approves the most expensive drug ever for use by the NHS, Jack Goddard takes a look at drug …
NICE recommends new triple therapy for multiple myeloma patients
March 19, 2021Medical Communications NHS England, NICE, oncology
A new second line triple therapy is to be offered to NHS patients in England with multiple myeloma, following a …
AstraZeneca & MSD ovarian cancer drug combination approved by NICE
March 19, 2021Medical Communications AstraZeneca, MSD, NICE, oncology
A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …
NICE recommends Daiichi Sankyo’s cholesterol-lowering treatments for NHS England use
March 18, 2021Daiichi Sankyo, NICE, cholesterol
NICE has recommended Daiichi Sankyo’s bempedoic acid and bempedoic acid/ezetimibe for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed …
NICE recommends £1.79m gene therapy for spinal muscular atrophy in babies
March 8, 2021Sales and Marketing NICE, spinal muscular atrophy
NICE is set to approve a new and potentially curative one-off gene therapy for babies with the rare genetic disorder …
Latest content
FibroFind appoints Lee Borthwick as CEO
